第一代与第二代分子分析测试:这两种测试如何指导早期激素受体阳性乳腺癌的决策?
Flora Nguyen Van Long1, Brigitte Poirier2, Christine Desbiens2
1Oncology Axis, Centre Hospitalier Universitaire de Québec Research Center - Université Laval (CRCHUQc-UL), Quebec city, QC G1V 4G2, Canada.
Cancer treatment reviews
|March 7, 2025
概括
像Oncotype DX和Prosigna这样的分子分析测试有助于个性化早期乳腺癌治疗. 这些测试评估复发风险和化疗益处,改善对激素受体阳性,HER2-阴性瘤的临床决策.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 临床决策支持 临床决策支持
背景情况:
- 激素受体阳性 (HR+) 和人体表皮生长因子受体2-阴性 (HER2-) 乳腺癌是常见的,但对辅助治疗的反应不同.
- 瘤异质性使治疗决策复杂化,可能导致仅基于临床和病理因素的过度治疗.
- 准确确定从辅助化疗中受益的患者是一个重大的临床挑战.
研究的目的:
- 为了比较Oncotype DX和Prosigna分子分析试验的优点和局限性.
- 讨论这些测试如何改善早期HR+/HER2-乳腺癌的临床决策.
- 识别知识缺口,并建议未来的研究方向.
主要方法:
- 对直接比较Oncotype DX和Prosigna的研究进行审查.
- 对分子测试的预后和预测能力的分析.
- 专注于早期,激素受体阳性乳腺癌的应用.
主要成果:
- 型DX和Prosigna都是早期乳腺癌的有效预后工具.
- 瘤型DX已经证明作为指导化疗决策的预测工具的实用性.
- 对比研究为这些分子测试的最佳使用提供了信息.
结论:
- 多基因分析分析对评估HR+乳腺癌复发风险和化疗反应有价值.
- 利用Oncotype DX和Prosigna的优势可以增强个性化的治疗策略.
- 需要进行进一步的研究,以解决乳腺癌分子测试中的剩余知识差距.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...